DIASORIN REGISTERED 5 HEPATITIS AND RETROVIRUSES ASSAYS IN BRAZIL ON LIAISON XL, BECOMING THE ONLY COMPANY WITH A COMPLETE SOLUTION FOR BLOOD BANKS IN BOTH CLIA AND ELISA TECHNOLOGY

July 11, 2013 - Saluggia (VC) - DiaSorin (FTSE MIB:DIA) is pleased to announce it received the marketing authorization for 5 LIAISON XL assays (HBsAg Quant, Anti-HBs II, HCV Ab, HIV Ab/Ag, recHTLV-I/II) related to Hepatitis and Retroviruses.

- **HBsAg Quant** for hepatitis B screening, diagnosis and monitoring: *quantitative determination of hepatitis B surface antigen (HBsAg)*
- **Anti-HBs II**, a critical HBV marker in establishing whether complete resolution of the infection has occurred as well as in establishing the acquisition of immunity whether acquired as a result of natural HBV infection or vaccination: *quantitative determination of antibody to hepatitis B surface antigen (anti-HBs)*
- **HCV Ab** for hepatitis C screening and diagnosis: *qualitative determination of specific antibodies to hepatitis C virus (anti-HCV)*
- **HIV Ab/Ag** for HIV screening and diagnosis: *combined qualitative determination of p24 antigen and specific antibodies to human immunodeficiency viruses*
- **recHTLV-I/II** for HTLV screening and diagnosis: *qualitative determination of specific antibodies to Human T-cell Lymphotropic Virus (HTLV) type I and type II*

The **Blood Banks Brazilian market is worth $ 50 million**, with **around 4.7 million of blood bags tested every year**. DiaSorin today **retains a market share of ca. 20%** of that market thanks to its high-quality Murex ELISA line.

With the launch of the **full panel of CLIA Hepatitis and Retroviruses assays, now available on the LIAISON XL**, DiaSorin completes the already available markers for Hepatitis B and Hepatitis A in CLIA technology and **is now positioned as the only company providing a complete solution for blood banks in both CLIA and ELISA technology.**
Mr. Carlo Rosa, Chief Executive Officer of DiaSorin Group, said: “I am proud to announce the registration of the new Hepatitis and Retroviruses assays in Brazil on our LIAISON XL platform. DiaSorin is today the only company with a complete solution for blood banks in both CLIA and ELISA technology in this country, with a market share of 20% thanks to the success of our high-quality Murex ELISA line.

The availability of these new LIAISON XL assays allows our Group to increase its market share in the Brazilian Hepatitis and Retroviruses market, confirming our commitment to reinforce our position as a key player in a 50 million dollars market, growing 15% every year and representing a strategic growth area for DiaSorin which aims to establish a long lasting leadership in this clinical area”.

**About DiaSorin**

Headquartered in Italy and listed in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostics (IVD) field. For over 40 years the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnostics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnostics market and new tests in the molecular diagnostics markets which identify DiaSorin Group as the IVD “diagnostics specialist”.

For additional information, please contact:

**Riccardo Fava**
External Relations Director - Head of IR and Media
Tel: +39.0161.487988
riccardo.fava@diasorin.it

**Margherita Sacerdoti**
Investor Relations Specialist
Tel: +39.0161.487456
margherita.sacerdoti@diasorin.it